What will be Pfizer's next move?????

Last week US treasury Department made a rule change that appeared to be aimed specifically at the transaction of Pfizer and allergan $ 160 Bn deal, stripping Pfizer of its benefits. 

With this deal Pfizer’s would have had relocated its headquarters to Ireland and shaved billions off its tax bill. Pfizer CEO Ian Read said in a brief statement: "We plan to make a decision about whether to pursue a potential separation of our innovative and established businesses by no later than the end of 2016.....

In terms of Biosimilars the question which comes in my mind is that will Pfizer keep the Biosimilar assets of the ongoing program of Allergan and Amgen ABP 215 (avastin Biosmilar) for NSCLC and ABP 980 (Transtuzumab biosimilar) into its own portfolio as its own pipeline PIII studies will be concluded in the later part. 

Also analyst belief that Pfizer will be in acquisition spree again and the target will be companies with attractive assets which may include Shire, Biogen, Regeneron and AbbVie. I believe that Pfizer may go ahead at the earliest for Biogen or Regeneron. In terms of biopharma/biosimilar prescriptive Biogen may be the next best deal for the company.